Stockreport

enGene CEO Pitches Detalimogene as Community-Friendly NMIBC Option, Teases Q2 LEGEND Data Update [Yahoo! Finance]

enGene Holdings Inc.  (ENGN) 
PDF response , mostly grade 1–2 catheter-related adverse events and low discontinuation rates, and expects a Q2 update on the primary "anytime CR" plus 12-month durability d [Read more]